Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.38 |
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296866 | 0.83 | CYP1A2 (0.48) | CYP1A2ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL2318612 | 0.77 | ESR1 (0.35) | CYP1A2ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL756551 | 0.76 | CYP2A6 (0.32) | — | |
| SCHEMBL1733533 | 0.76 | TRPM4 (0.37) | CYP1A2ALDH1A1MEN1KMT2ACASP7 | |
| SCHEMBL2257839 | 0.76 | CYP3A4 (0.50) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL644725 | 0.74 | CYP2A6 (0.48) | CYP1A2ALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL643621 | 0.74 | CYP2A6 (0.48) | ALDH1A1ESR2ESR1CYP3A4DYRK1A | |
| SCHEMBL644839 | 0.74 | CYP1A2 (0.48) | CYP1A2ALDH1A1CA2NPC1RAB9A | |
| SCHEMBL18242373 | 0.74 | — | — | |
| SCHEMBL645539 | 0.74 | CYP2A6 (0.48) | CYP1A2ALDH1A1CYP3A4HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | claimed |
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | claimed |
| US-9371286-B2 | Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-21 | — | — | US | claimed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | claimed |
| US-20140315947-A1 | PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2014-10-23 | — | — | US | claimed |
| US-8569505-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | claimed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| EP-2576543-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | claimed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | claimed |
| US-6984647-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-10 | — | — | US | claimed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | claimed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | claimed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | CYP1A2 4265/4885ALDH1A1 2811/4885MEN1 2329/4885 |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | CYP1A2 101/4885ALDH1A1 848/4885MEN1 4654/4885 |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | CYP1A2 1755/4885ALDH1A1 1884/4885MEN1 4110/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | CYP1A2 4265/4885ALDH1A1 2811/4885MEN1 2329/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | CYP1A2 238/4885ALDH1A1 2299/4885MEN1 4832/4885 |
| US-20140315947-A1 | PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS | UQCRB, UQCRC1, UQCRC2 | CYP1A2 3693/4885ALDH1A1 2079/4885MEN1 4790/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | CYP1A2 1977/4885ALDH1A1 1371/4885MEN1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.